Prostaglandin analogues: past, present, and future

Astakhov, Yury S.; Сергеевич, Астахов Юрий; Nechiporenko, P. A.; Андреевич, Нечипоренко Павел

doi:10.17816/ov10140-52

Cited by 13 publications

(3 citation statements)

References 82 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Более подробно остановимся еще на одном осложнении, связанном с использованием препаратов группы АПГ, которое в отечественной литературе или не упоминается вообще, или описывается как «редкое явление», «не приводящее к отмене инстилляций», -это простагландин-ассоциированная периорбитопатия (ПАП) [27,36].…”

Section: а бunclassified

See 1 more Smart Citation

Adverse effects of prostaglandin analogues used in ophthalmological practice

Казанова

2021

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

Prostaglandin analogues are a class of antihypertensive drugs for glaucoma treatment which are systematically safe but have a sufficiently large number of local side effects. These effects may worsen the quality of life of patients with glaucoma and reducetheir adherence to treatment routines due to physical and psychological discomfort. The review presents literature data and clinical cases fromthe author’s own medical practice.

show abstract

Section: а бunclassified

“…Изменение цвета радужки -появляется этот эффект уже через 1-4 мес после начала закапывания АПГ [27][28][29]. К сожалению, является необратимым даже после пр екращения терапии [23,30].…”

unclassified

Adverse effects of prostaglandin analogues used in ophthalmological practice

Казанова

2021

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

show abstract

“…Ими было установлено, что пациенты, гомозиготные по Gln 27, при лечении местными бета-блокаторами имели достоверно лучший фармакологический ответ, который проявлялся снижением ВГД [27,48]. Однако другие исследователи пришли к заключению, что нет ассоциаций между полиморфизмами гена β 2 -адренорецептора и клинической эффективностью проводимого лечения [49,50]. Более того, Inagaki Y и соавт.…”

Section: персонализированная терапияunclassified

Practical pharmacogenetics for personalized management of glaucoma patients

Soshina

Turkina

2020

Fgen_Fgenom

View full text Add to dashboard Cite

At present, taking into account the widespread application of pharmacogenetics’ achievements to all branches of medicine, it has become possible to conduct such research in ophthalmology. At the moment, the studies on the most broadly used glaucoma medications have been carried out. The correlations between patients’ genotypes and the frequency of occurrence of adverse side effects have been found. The further exploration of the pharmacogenetics of the glaucoma medications and the introduction of pharmacogenetic testing will enable ophthalmologists to assign a rational, safe, and effective treatment in the short time, which will considerably improve the quality of provided aid.

show abstract

Efficacy and safety of travoprost in patients with primary open-angle glaucoma

et al. 2019

View full text Add to dashboard Cite

Purpose-to study the hypotensive efficacy and safety of Travapress (0.004% travoprost) in patients with primary open-angle glaucoma (POAG). Material and methods. The study included 50 patients (91 eyes) aged 45 to 74 years. The first group consisted of 23 patients (41 eyes) who received monotherapy with Travaprost. Patients of the second group (27 patients, 50 eyes) Travaprost was added to therapy with timolol 0.5% (17 patients, 32 eyes) or dorzolamide 2% (10 patients, 18 eyes). Travaprost was given for a period of 6 months. IOP was determined in 2 weeks, 1, 3 and 6 months from the beginning of treatment and daily IOP measurement was at 10.00, 12.00, 14.00 and 16.00. Subjective symptoms were evaluated in points by special scales. Results. The study was completed by 42 patients (84%, 79 eyes). Two patients (4.7%) has stopped to use Travapress due to the side effects. Local side effects were observed in 9 patients (21.4%) with mild hyperemia being the most common and seen in 5 patients (11.9%). In the first group, the maximum IOP decrease was recorded for 3 months of the study and amounted to 7.3±1.2 mm Hg (27.5%) compared to baseline. By 6 months, IOP decreased by 6.8±1.5 mm Hg on average (25.6%). In the second group in the subgroup with timolol 0,5% IOP decreased by 4,9±1.7 mm Hg (20%) compared to baseline, in the subgroup with dorzolamid 2%-by 4,3±1,3 mm Hg (16,9%) compared to baseline. Evening use the drug was accompanied by significantly lower levels of daily IOP fluctuations compared with morning intake (3.0±1.2 and 3.8±1.7 mm Hg, respectively, p = 0,002). Conclusion. Travapress was established as highly efficient and safe. It can be recommended for wide use in the treatment of patients with POAG.

show abstract

Prostaglandin analogues: past, present, and future

Abstract: This literature review is focused on the prostaglandin topical analogues and describes peculiarities of their structure, pharmacokinetics and pharmacodynamics, results of clinical trials and meta-analyzes, as well as modern trends in the topical IOP-lowering glaucoma therapy evolution.

Cited by 13 publications

References 82 publications

Adverse effects of prostaglandin analogues used in ophthalmological practice

Adverse effects of prostaglandin analogues used in ophthalmological practice

Practical pharmacogenetics for personalized management of glaucoma patients

Efficacy and safety of travoprost in patients with primary open-angle glaucoma

Contact Info

Product

Resources

About